glp-1 drugs pills The next phase of the obesity drug race GLP-1 pills are on the

Its about to get a lot harder to get cheap GLP-1s: Rising costs may force consumers to cut back on discretionary spending, creating headwinds for retailers already fearing tariff-driven cost increases.

Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.

Therefore, there is a need to identify those potential changes and adjust patients medication doses in order to achieve higher efficacy and avoid toxicity.

Had missed this detail @Humana was selected by CMS as the central processor for the Medicare GLP-1 Bridge Makes sense given Humana already administers prescription drug access for the LI NET program

Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP1-based obesity pharmacotherapy.

This is where wellness starts to collide with pharma